Abstract
A group of 28 previously untreated patients with locally advanced or metastatic adenocarcinoma of the pancreas were entered in this phase I/II study. Treatment consisted of oral dexverapamil 1000–1200 mg/day for 3 days, epirubicin given as an intravenous bolus injection on day 2 with a starting dose of 90 mg/m2, and 400 μg granulocyte/macrophage-colony-stimulating factor (GM-CSF) administered subcutaneously from day 5 through 14. Epirubicin dose escalation levels were 90, 105, 120 and 135 mg/m2. Consecutive cohorts of 4–8 patients were planned at each dose level. Treatment cycles were repeated every 3 weeks. Haematological toxicity, specifically granulocytopenia constituted the dose-limiting toxicity with a maximum tolerated dose of 120 mg/m2 for epirubicin. Despite routine supportive therapy with GM-CSF, 4, 2, and 5 patients experienced grade 4 granulocytopenia during their first two treatment courses at levels of 105, 120, and 135 mg/m2 respectively. Non-haematological toxicity was uncommon, generally modest, and did not demonstrate a clear relationship with the anthracycline dose. Dexverapamil-related cardiovascular symptoms occurred frequently, but they never resulted in serious toxicity requiring active medical intervention or permanent discontinuation of therapy. Of the 28 patients, 9 achieved partial responses to this therapy. The recommended dose of epirubicin for this regimen with dexverapamil and GM-CSF is 120 mg/m2 every 3 weeks. Therapeutic results suggest this regimen to be an effective and tolerable treatment strategy in pancreatic cancer, which should be evaluated further.
Key words: Dexverapamil, Multidrug resistance, Pancreatic cancer
Abbreviations
- DVPM
dexverapamil
- ECG
electrocardiogram
- GM-CSF
recombinant human granulocyte-macrophage-colony-stimulating factor
- MDR
multidrug resistance
- MTD
maximum tolerated dose
References
- Altavilla S, Adaao V, Alafaci E, et al (1991) High dose epirubicin in the treatment of advanced adenocarcinoma of the pancreas (abstract). Eur J Cancer 27 [Suppl 2]:74 [Google Scholar]
- Bonadonna G, Gianni L, Santoro A, et al (1993) Drugs ten years later: epirubicin. Ann Oncol 4:359–369 [DOI] [PubMed] [Google Scholar]
- Brennan MF, Kinsella TJ, Casper ES (1993) Cancer of the pancreas. In: De Vita VT, Hellman S, Rosenberg SA (eds) Cancer: principles and practice of oncology, 4th edn. Lippincott Philadelphia, pp 849–882 [Google Scholar]
- Echizen H, Brecht T, Niedergesass S, et al (1985) The effect of dextro-levo-, and racemic verapamil on atrioventricular conduction in humans. Am Heart J 109:210–214 [DOI] [PubMed] [Google Scholar]
- Goldstein LJ, Galski H, Fojo A, et al (1989) Expression of a multidrug resistance gene in human cancers. J Natl Cancer Inst 81:116–123 [DOI] [PubMed] [Google Scholar]
- Kerr DJ, Graham J, Cummings J (1986) The effect of verapamil on the pharmacokinetics of Adriamycin. Cancer Chemother Pharmacol 18:239–242 [DOI] [PubMed] [Google Scholar]
- Loven D, Figer A, Vigler N, et al (1989) Epirubicin in the treatment of advanced carcinoma of the pancreas (abstract). Proc Am Soc Clin Oncol 8:113 [Google Scholar]
- Lum BL, Kaubisch S, Yahanda AM, et al (1992) Alteration of etoposide pharmacokinetics and pharmacodynamics by cyclosporine in a phase I trial to modulate multidrug resistance. J Clin Oncol 10:1635–1642 [DOI] [PubMed] [Google Scholar]
- Pastan I, Gottesman MM (1987) Multidrug resistance in human cancer. N Engl J Med 316:1388–1393 [DOI] [PubMed] [Google Scholar]
- Plumb JA, Milroy R, Kaye SB (1990) The activity of verapamil as a resistance modifier in vitro in drug-resistant human tumour cell lines is not stereospecific. Biochem Pharmacol 39:787–792 [DOI] [PubMed] [Google Scholar]
- Scheithauer W, Schenk T, Czejka M (1993) Pharmacokinetic interaction between epirubicin and the multidrug resistance reverting agent d-verapamil. Br J Cancer 68:8–9 [DOI] [PMC free article] [PubMed] [Google Scholar]
- Schulz G, Frisch J, Greifenberg B, et al (1991) New therapeutic modalities for the clinical use of rhGM-CSF in patients with malignancies. Am J Clin Oncol 14 [Suppl 1]:19–26 [DOI] [PubMed] [Google Scholar]
- Wils J, Bleiberg J, Blijham G, et al (1995) Phase II study of epirubicin in advanced adenocarcinoma of the pancreas. Eur J Cancer Clin Oncol 21:191–194 [DOI] [PubMed] [Google Scholar]
- Yahanda ABM, Adler KM, Fisher GA, et al (1992) Phase I trial of etoposide with cyclosporine as a modulator of multidrug resistance. J Clin Oncol 10:1624–1634 [DOI] [PubMed] [Google Scholar]